Apretude™ (cabotegravir) – New drug approval
On December 20, 2021, the FDA announced the approval of ViiV Healthcare’s Apretude (cabotegravir), in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired human immunodeficiency virus (HIV)-1 infection.
Top